Answers are grounded in this paper and cite their sources.
Rationale: Anti-EGFR therapy improves outcomes in patients with RAS wild-type metastatic colorectal cancer (mCRC), but acquired resistance frequently emerges, and its mechanisms are heterogeneous. This report describes 2 patients with RAS wild-type mCRC who developed acquired resistance to anti-EGFR therapy. Patient concerns: Both patients had RAS wild-type mCRC with multiple liver metastases and received cetuximab-based therapy as first-line treatment. Each patient experienced disease progression during treatment. Diagnoses: Case 1: a Kirsten rat sarcoma viral oncogene homolog exon 2 codon 12 mutation was detected in a liver metastasis at the time of progression, whereas the primary tumor remained RAS wild-type. Case 2: human epidermal growth factor receptor 2 (HER2) overexpression (immunohistochemistry 3+) was identified in the primary tumor on molecular reassessment after progression. Interventions: Case 1 received cetuximab plus mFOLFOX6 followed by cetuximab-based maintenance; after progression, molecular analysis of the liver metastasis detected a Kirsten rat sarcoma viral oncogene homolog mutation, anti-EGFR therapy was discontinued and switched to FOLFIRI plus bevacizumab, and the patient subsequently underwent liver metastasectomy, with quarterly liquid biopsies for monitoring. Case 2 received cetuximab plus mFOLFOX6 followed by cetuximab plus 5-fluorouracil; after HER2 amplification was confirmed, treatment was switched to trastuzumab plus pertuzumab combined with chemotherapy, and surgery was deferred. Outcomes: At the last follow-up, case 1 had stable disease with undetectable RAS-mutated circulating tumor DNA after metastasectomy and continued chemotherapy. Case 2 showed gradual disease progression despite HER2-directed therapy and required further-line treatment. Lessons: These 2 cases illustrate that acquired resistance to anti-EGFR therapy is a dynamic and heterogeneous process rather than a single event, and they support repeated molecular profiling of metastatic lesions to guide subsequent treatment selection.
No takes yet. Share an insight, caveat, or question.
Song et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: